Dermata Therapeutics (DRMA) Competitors $0.81 -0.02 (-2.89%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRMA vs. LPCN, MIRA, CING, UPXI, GLYC, COCP, BFRG, SNYR, EQ, and LPTXShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Lipocine (LPCN), MIRA Pharmaceuticals (MIRA), Cingulate (CING), Upexi (UPXI), GlycoMimetics (GLYC), Cocrystal Pharma (COCP), Bullfrog AI (BFRG), Synergy CHC Corp. (Uplisting) (SNYR), Equillium (EQ), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. Lipocine MIRA Pharmaceuticals Cingulate Upexi GlycoMimetics Cocrystal Pharma Bullfrog AI Synergy CHC Corp. (Uplisting) Equillium Leap Therapeutics Dermata Therapeutics (NASDAQ:DRMA) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking. Which has better earnings & valuation, DRMA or LPCN? Dermata Therapeutics has higher earnings, but lower revenue than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDermata TherapeuticsN/AN/A-$7.80M-$16.41-0.05Lipocine$11.20M1.65-$16.35M-$0.01-345.00 Do analysts prefer DRMA or LPCN? Dermata Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 637.10%. Lipocine has a consensus price target of $10.00, indicating a potential upside of 189.86%. Given Dermata Therapeutics' higher probable upside, analysts clearly believe Dermata Therapeutics is more favorable than Lipocine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Lipocine 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of DRMA or LPCN? 8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 9.4% of Dermata Therapeutics shares are owned by insiders. Comparatively, 6.1% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, DRMA or LPCN? Dermata Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Does the MarketBeat Community prefer DRMA or LPCN? Lipocine received 342 more outperform votes than Dermata Therapeutics when rated by MarketBeat users. Likewise, 66.99% of users gave Lipocine an outperform vote while only 50.00% of users gave Dermata Therapeutics an outperform vote. CompanyUnderperformOutperformDermata TherapeuticsOutperform Votes550.00% Underperform Votes550.00% LipocineOutperform Votes34766.99% Underperform Votes17133.01% Is DRMA or LPCN more profitable? Lipocine's return on equity of -19.17% beat Dermata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dermata TherapeuticsN/A -247.39% -179.72% Lipocine N/A -19.17%-17.60% Does the media refer more to DRMA or LPCN? In the previous week, Lipocine had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for Dermata Therapeutics. Dermata Therapeutics' average media sentiment score of 1.43 beat Lipocine's score of 0.62 indicating that Dermata Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Dermata Therapeutics Positive Lipocine Positive SummaryLipocine beats Dermata Therapeutics on 9 of the 14 factors compared between the two stocks. Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMA vs. The Competition Export to ExcelMetricDermata TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.91M$6.72B$5.49B$7.97BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-0.057.3622.6118.58Price / SalesN/A241.71397.51103.15Price / CashN/A65.8538.1834.62Price / Book0.036.486.704.26Net Income-$7.80M$143.43M$3.22B$248.31M7 Day Performance8.53%1.69%1.26%1.34%1 Month Performance-18.58%6.58%3.73%3.92%1 Year Performance-83.68%-2.63%15.82%5.33% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMADermata Therapeutics2.9196 of 5 stars$0.81-2.9%$6.00+637.1%-82.9%$4.91MN/A-0.058Upcoming EarningsPositive NewsLPCNLipocine2.4982 of 5 stars$3.28+2.8%$10.00+204.9%-28.4%$17.55M$11.20M-4.3210Upcoming EarningsAnalyst ForecastNews CoverageMIRAMIRA Pharmaceuticals2.8431 of 5 stars$1.03-1.0%$14.00+1,259.2%+36.5%$17.32MN/A-1.842Short Interest ↓CINGCingulate2.5213 of 5 stars$4.35+1.2%$30.67+605.0%+350.8%$17.14MN/A-0.3020Short Interest ↑News CoverageUPXIUpexi0.9718 of 5 stars$12.92-16.7%N/A+9.4%$17.07M$18.63M0.00130Short Interest ↑High Trading VolumeGLYCGlycoMimetics2.0967 of 5 stars$0.26-0.2%N/A-86.0%$16.81M$10,000.00-0.4450Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageCOCPCocrystal Pharma2.4954 of 5 stars$1.65-3.5%$7.00+324.2%-4.4%$16.78MN/A-0.8910Gap UpBFRGBullfrog AI0.4719 of 5 stars$1.77-4.3%N/A-43.6%$16.67M$60,000.00-2.084Short Interest ↑SNYRSynergy CHC Corp. (Uplisting)3.5374 of 5 stars$1.92+19.3%$10.00+420.8%N/A$16.46M$34.83M0.0040Positive NewsEQEquillium2.797 of 5 stars$0.46+4.5%$3.00+555.0%-71.8%$16.36M$41.10M-3.2740Upcoming EarningsShort Interest ↓Gap UpLPTXLeap Therapeutics2.6186 of 5 stars$0.40-1.1%$4.92+1,142.8%-86.5%$16.32MN/A-0.2040Gap Down Related Companies and Tools Related Companies LPCN Competitors MIRA Competitors CING Competitors UPXI Competitors GLYC Competitors COCP Competitors BFRG Competitors SNYR Competitors EQ Competitors LPTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRMA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DRMA Stock Free DRMA Stock Alerts